SC1: TRANSIENT PROTEIN EXPRESSION: A KEY TOOL TO ENABLE RAPID PROTEIN ENGINEERING
MONDAY 12 NOVEMBER | 09:00 - 12:00
Room Location: Room 5A
Instructors:
Richard Altman, MS, Scientist, Protein Technologies, Amgen
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
This short course introduces both the fundamental concepts and technologies needed to establish transient protein production in mammalian cells, which has become an essential tool to enable rapid protein engineering. Transient expression allows for the rapid generation, purification and characterization of milligram-to-gram quantities of secreted or intracellular recombinant proteins for therapeutic, functional and structural studies. The course combines instruction and case studies in an interactive environment.
DETAILED AGENDA:
09:00 Opening Remarks/Introductions
Richard Altman, MS, Scientist, Protein Technologies, Amgen
09:05 Fundamental Elements of Transient Protein Production
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
- Available transient expression systems
- DNA vector elements for enhanced protein production
10:00 Fundamental Elements of Transient Protein Production
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
- HEK293 vs. CHO
- The interplay of cells, medium, transfection reagent, and supplements
- Key considerations for maximizing yields
10:30 Coffee Break
10:50 Fundamental Elements of Transient Protein Production (cont.)
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
11:15 Implementing Transient Protein Production
Richard Altman, MS, Scientist, Protein Technologies, Amgen
- What are your goals/objectives for transient protein expression?
- Case studies
- Assembling an effective mammalian expression toolbox
- Optimizing the total protein expression process
12:00 Close of Course
Instructors Biographies:
Richard Altman, MS, Scientist, Protein Technologies, Amgen
Rich Altman has 30 years of experience working in the pharmaceutical industry. In early 2016, he joined the Protein Technologies Mammalian Expression group at Amgen San Francisco, supporting biologics drug development. Prior to Amgen, he worked for several pharmaceutical companies on the cloning, expression, purification and characterization of recombinant proteins. This work supported both small-molecule high-throughput screening and protein therapeutic efforts. He received his MS degree from the University of Pittsburgh School of Medicine in the Department of Molecular Biology and Biochemistry.
Henry C. Chiou, PhD, Director, Cell Biology, Life Science Solutions, Thermo Fisher Scientific
Dr. Chiou has over 15 years of experience working on development of mammalian protein expression systems and transfection reagents. For the past nine years, he has worked as a principal scientist and now in product development and portfolio management for Life Technologies, now part of Thermo Fisher Scientific. He has led the development efforts on a number of products, including the FreeStyle™ transient expression systems, Lipofectamine™ LTX and Lipofectamine™ RNAiMAX. Prior to Life Technologies, he worked for several biotech companies on biotherapeutic gene delivery systems. Dr. Chiou received his doctorate from Harvard University and completed a postdoctoral fellowship at the University of Pennsylvania.
Dominic Esposito, PhD, Director, Protein Expression Laboratory, Frederick National Laboratory for Cancer Research
Dr. Esposito is currently the Director of the Protein Expression Laboratory (PEL) at the Frederick National Laboratory for Cancer Research. The PEL is currently focused on providing production of Ras and Ras-related proteins for the National Cancer Institute’s RAS Initiative. These proteins are being used for a wide-ranging attack on Ras biology including structural biology, biophysics, and development of screens and assays for drug discovery. In addition, the PEL still assists in the generation of proteins of interest to investigators in the intramural program of the NCI, and invents and develops new technologies for protein expression and production. Dr. Esposito received his BA in Chemistry at La Salle University in Philadelphia, and his PhD in Biochemistry at the Johns Hopkins University Bloomberg School. Dr. Esposito previously worked for Life Technologies, where he helped to develop the Gateway recombinational cloning system.